Alzamend neuro announces initiation date of first phase ii clinical trial of al001 to take place at massachusetts general hospital

Atlanta, feb. 25, 2025 (globe newswire) -- alzamend neuro, inc. (nasdaq: alzn) (“alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer's disease (“alzheimer's”), bipolar disorder (“bd”), major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”), today announced its plans to initiate the first of five highly anticipated phase ii clinical studies of al001, with the first study, in healthy human subjects, expected to commence in the second quarter of 2025. this study follows the successful development of a novel head coil by tesla dynamic coils bv, a key component of the clinical trial.
GM Ratings Summary
GM Quant Ranking